跳至主要内容
临床试验/CTRI/2019/09/021082
CTRI/2019/09/021082尚未招募未知

eoadjuvant treatment versus upfront surgery in Resectablepancreatic cancer (NEVUS)

Tata Memorial Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Radiologically defined to be resectable as per the NCCN guidelines Version 2 on a Triphasic CECT scan amenable to oncological surgical resection. Selected ampullary adenocarcinomas involving pancreatic head or abutting or involving vessels will be included.
  • -Patients with no evidence of regional or distant metastatic disease based on CT scan of the chest/ abdomen/pelvis
  • -No significant co-morbidities that would interfere with treatment and fit for general anaestheia
  • -Reliable for follow-up and signed informed consent.
  • -Karnofsky performance status (KPS) between 70 and 100.
  • -Patients with tumors primarily of the body or tail of the pancreas requiring a distal pancreaticoduodenectomy.

排除标准

  • -Prior surgical resection of any pancreatic malignancy
  • -Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
  • -History of prior allergic reactions attributed to compounds of CT or MRI contrast
  • -Any prior therapy for pancreatic cancer

研究者

相似试验